Advertisement

Topics

Press Releases about Biotechnology, Pharmaceutical and Healthcare

03:18 EST 6th December 2016 | BioPortfolio

Latest biotech, pharma, healthcare and medical device news.

Showing News Articles 1–25 of 110,000+

Tuesday 6th December 2016

MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016

MorphoSys AG / MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016 . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Updated Results Include Clinical Response Rates from Ongoing Phase 1/2a Study with MOR202 in Patients with Relapsed / Refractory Multiple Myeloma MorphoSys AG (F...

MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference:

MorphoSys AG / MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference: . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today the presentation of updated safety and efficacy d...

Monday 5th December 2016

BrainStorm to Host Year End Call with Investors to Discuss Important Corporate Developments

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 6, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call on December 19 at 8:30 am Eastern Time. Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer, will...

KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology

Dateline City: KENILWORTH, N.J. Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR o...

Hutchison China Meditech Limited: HMPL-523 Pre-clinical Data Presented at ASH

HONG KONG, CHINA -- (Marketwired) -- 12/06/16 -- Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM) Press Release Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting London: Tuesday, December 6, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that data from a recent pre-cli...

WAO International Scientific Conference (WISC 2016) Opens Today in Jerusalem

World Allergy Organization (WAO) Explores Future of Allergy Patient Care Jerusalem, Israel (PRWEB) December 05, 2016 The WAO International Scientific Conference (WISC) 2016 opens today in Jerusalem. Running from 6-9 December, the conference of the World Allergy Organization (WAO) will present new research in allergy/clinical immunology medicine to practicing physicians and clinical researchers. A...

Santa Makes Cyber-Stop to Shriners Hospitals for Children® — Los Angeles for the Holidays

Dimension Data will bring the magic of collaboration technology to patients of Shriners Hospitals for Children in Los Angeles, Philadelphia and Chicago. Los Angeles (PRWEB) December 05, 2016 What: Shriners Hospitals for Children, with the help of Dimension Data, will bring a live feed of the North Pole to our patients – using a video monitor and web-enabled camera. Santa visits with children th...

Immunohistochemistry Market by Product Application & Drug Testing) End User - Global Forecast to 2021

LONDON, Dec. 5, 2016 /PRNewswire/ -- The immunohistochemistry (IHC) market is projected to reach USD 2.12 Billion by 2021, growing at a CAGR of 7.3% during the forecast period of 2016 to 2021. Factors such as the growing prevalence of cancer and rapidly increasing geriatric population across the globe are the primary driving the growth of this market. Other factors driving the IHC market growth in...

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market Size & Forecast By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow, By End Use And Trend Analysis From 2013 To 2024

LONDON, Dec. 5, 2016 /PRNewswire/ -- U.S. clinical oncology next generation sequencing market is anticipated to reach USD 1.53 billion by 2024, according to a new report by Grand View Research, Inc. Application of NGS platform for clinical oncology are expected to grow at a steady pace under the influence of increasing adoption of NGS platforms in oncology R&D coupled with rising incidents of ...

United Kingdom Ophthalmic Devices Market Outlook to 2022 - Cataract Surgery Devices, Intraocular Lens (IOL), Vitreo Retinal Surgery Devices, Glaucoma Surgery Devices, Ophthalmic Lasers, Ophthalmic Diagnostic Equipment and Vision Care

LONDON, Dec. 5, 2016 /PRNewswire/ -- United Kingdom Ophthalmic Devices Market Outlook to 2022 - Cataract Surgery Devices, Intraocular Lens (IOL), Vitreo Retinal Surgery Devices, Glaucoma Surgery Devices, Ophthalmic Lasers, Ophthalmic Diagnostic Equipment and Vision CareSummaryGlobalData's new report, "United Kingdom Ophthalmic Devices Market Outlook to 2022", provides key market data on the United...

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016

LONDON, Dec. 5, 2016 /PRNewswire/ -- Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2016, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline landscape.Gastroesophage...

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016

LONDON, Dec. 5, 2016 /PRNewswire/ -- Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.H5N1 is a type of i...

Gingivitis - Pipeline Review, H2 2016

LONDON, Dec. 5, 2016 /PRNewswire/ -- Gingivitis - Pipeline Review, H2 2016SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gingivitis – Pipeline Review, H2 2016, provides an overview of the Gingivitis (Mouth And Dental Disorders) pipeline landscape.Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. Symptoms include sensit...

Knee Implants Market Analysis By Procedure Type (Total, Partial, Revision Knee Replacement), By Component Type (Fixed-Bearing, Mobile-Bearing Implants), And Segment Forecasts To 2024

LONDON, Dec. 5, 2016 /PRNewswire/ -- The global knee implant market was valued at USD 8.8 billion in 2015 and is expected to reach a value of USD 12.4 billion by 2024. This growth is majorly attributed to growing elderly population and surging prevalence of chronic rheumatic conditions such as osteoarthritis, rheumatoid arthritis, and post-traumatic arthritis. Primary factors that lead to the occu...

TiGenix announces launch of proposed initial public offering in the United States

PRESS RELEASE REGULATED INFORMATION TiGenix announces launch of proposed initial public offering in the United States Leuven (BELGIUM) - December 5, 2016, 22:01h CET - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced tod...

United Kingdom Ophthalmic Diagnostic Equipment Market Outlook to 2022

LONDON, Dec. 5 2016 /PRNewswire/ -- United Kingdom Ophthalmic Diagnostic Equipment Market Outlook to 2022SummaryGlobalData's new report, "United Kingdom Ophthalmic Diagnostic Equipment Market Outlook to 2022", provides key market data on the United Kingdom Ophthalmic Diagnostic Equipment market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within...

France Glaucoma Surgery Devices Market Outlook to 2022

LONDON, Dec. 5, 2016 /PRNewswire/ -- France Glaucoma Surgery Devices Market Outlook to 2022SummaryGlobalData's new report, "France Glaucoma Surgery Devices Market Outlook to 2022", provides key market data on the France Glaucoma Surgery Devices market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segements - Canaloplasty Micro Cathe...

Spain Glaucoma Surgery Devices Market Outlook to 2022

LONDON, Dec. 5, 2016 /PRNewswire/ -- Spain Glaucoma Surgery Devices Market Outlook to 2022SummaryGlobalData's new report, "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides key market data on the Spain Glaucoma Surgery Devices market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segements - Canaloplasty Micro Catheter...

New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®)

NORTH CHICAGO, Ill., Dec. 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced efficacy and safety findings from a Phase 2 study demonstrating that nearly half (48%) of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) had a complete or partial response with single-agent ibrutinib (IMBRUVICA®), as assessed by Independent Rev...

New Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin's Lymphoma

SAN DIEGO and RARITAN, N.J., Dec. 5, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced results from a Phase 2 study demonstrating a 48% overall response rate (ORR) as assessed by an Independent Review Committee (IRC) with single-agent ibrutinib (IMBRUVICA®) in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). These data will be...

Mediaplanet Teams up with the Anita Kaufman Foundation for “Epilepsy Awareness” Campaign

Over 3 million Americans are currently dealing with an epilepsy diagnosis. More than 200,000 people are newly diagnosed every single year. (PRWEB) December 05, 2016 “Epilepsy Awareness,” which can be found at the American Epilepsy Society’s 70th Annual Meeting through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the social stigma and lack of public education...

Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin's Lymphoma (T-cell NHL) at ASH 2016

CRANBURY, N.J., Dec. 5, 2016 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a privately held, clinical-stage, oncology-focused pharmaceutical company, today presented data from two Phase I trials evaluating its lead compound, CPI-613, in poster sessions at the 58th annual meeting of the American Society of Hematology (ASH) in San Diego, California. The two datasets show encouraging effica...

Johns Hopkins All Children's Hospital Researchers Studying Impacts of Concussion Through Unique Mouth Guards

Johns Hopkins All Children’s Hospital researchers are studying concussions in student athletes by monitoring hits to the head through mouth guards that track the location and force of the hit. St. Petersburg, Fla. (PRWEB) December 05, 2016 Researchers at Johns Hopkins All Children’s Hospital want to learn more about the effects concussions have on the growing brains of young athletes. Over th...

Zimmer Biomet Announces the Early Tender Results and Upsizing of Its Cash Tender Offers for Certain Outstanding Debt Securities

WARSAW, Ind., Dec. 5, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today announced that, pursuant to its previously‑announced cash tender offers (the "Offers") for the debt securities identified in the table below (collectively, the "Notes"), approximately $2.6 billion in aggregate principal amount of Notes were validly tendered and not val...

Riversand is Named a Leader in the 2016 Product Information Management (PIM) Report

Riversand is ranked among the top 2 in strategy category Houston, TX (PRWEB) December 05, 2016 Riversand, a leading provider of Product Information Management (PIM) and Multi-Domain Master Data Management (MDM) solutions, today announced that they were named as a leader in the Forrester Research, Inc. November 2016 report, The Forrester Wave™: Product Information Management Solutions, Q4 2016. ...


Quick Search
Advertisement